Original from:Genomeweb
Image Credit: Roche
Roche announced on Thursday that its new Cobas 5800 molecular instrument has received CE marking.
The platform builds on Roche's Cobas menu, which includes its Cobas 6800 and 8800 instruments, and provides a more compact module with a fully automated workflow.
The real-time PCR-based instrument delivers up to 144 results in an eight-hour shift and offers a workflow that includes sample supply, transfer and preparation, amplification and detection, result calculation, and delivery to the laboratory information system, Roche said in a statement.
The Cobas 5800 will offer the same test menu as the 6800 and 8800 systems, including the Cobas SARS-CoV-2 test, Roche added. Other tests on Roche's Cobas menu are its BK polyomavirus assay, HIV-1/HIV-2 Qualitative test, and Epstein-Barr virus test.
"This new system helps to address the high demands on labs through greater efficiency, optimized workflows and cost savings, enabling them to deliver quality patient care," Roche Diagnostics CEO Thomas Schinecker said in a statement.
The Basel, Switzerland-based company said it anticipates receiving US Food and Drug Administration approval for the platform during the third quarter of 2022.
Copyright © 2025 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.